These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


769 related items for PubMed ID: 22204436

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B, Bonnard C, Renard E.
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [Abstract] [Full Text] [Related]

  • 3. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S.
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 5. The potential for renoprotection with incretin-based drugs.
    Tanaka T, Higashijima Y, Wada T, Nangaku M.
    Kidney Int; 2014 Oct 29; 86(4):701-11. PubMed ID: 25007170
    [Abstract] [Full Text] [Related]

  • 6. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
    Lee YS, Jun HS.
    Metabolism; 2014 Jan 29; 63(1):9-19. PubMed ID: 24140094
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Incretins and Their Endocrine and Metabolic Functions.
    Seufert J.
    Endocr Dev; 2017 Jan 29; 32():38-48. PubMed ID: 28873383
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Deacon CF.
    Diabetes Obes Metab; 2007 Sep 29; 9 Suppl 1():23-31. PubMed ID: 17877544
    [Abstract] [Full Text] [Related]

  • 15. Glucagon-like peptide 1 (GLP-1) and metabolic diseases.
    Rotella CM, Pala L, Mannucci E.
    J Endocrinol Invest; 2005 Sep 29; 28(8):746-58. PubMed ID: 16277173
    [Abstract] [Full Text] [Related]

  • 16. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ.
    Med Clin (Barc); 2014 Sep 29; 143 Suppl 2():2-7. PubMed ID: 25437458
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no.
    Madsbad S.
    Eur J Intern Med; 2012 Mar 29; 23(2):132-6. PubMed ID: 22284242
    [Abstract] [Full Text] [Related]

  • 19. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M.
    Diabetes Obes Metab; 2013 Jul 29; 15(7):593-606. PubMed ID: 23216746
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 39.